CET

Stellantis to Celebrate Opening of its First Circular Economy Hub on November 23

Retrieved on: 
Wednesday, November 15, 2023

AMSTERDAM, November 15, 2023 – Stellantis N.V. announced today it will celebrate the official opening of its first SUSTAINera Circular Economy Hub within the Mirafiori complex in Turin, Italy on November 23, 2023, at 2:30 p.m. CET / 8:30 a.m. EST.

Key Points: 
  • AMSTERDAM, November 15, 2023 – Stellantis N.V. announced today it will celebrate the official opening of its first SUSTAINera Circular Economy Hub within the Mirafiori complex in Turin, Italy on November 23, 2023, at 2:30 p.m. CET / 8:30 a.m. EST.
  • John Elkann, Chairman of Stellantis, and Carlos Tavares, CEO of Stellantis, will inaugurate the operations and attend the ribbon-cutting.
  • The Circular Economy Hub is home to activities supporting a sustainable business model for parts and vehicles, including parts and electric vehicle battery remanufacturing, vehicle reconditioning, and vehicle dismantling, with the scope set to expand globally.
  • Streaming video of the event will be available at 2:30 p.m. CET / 8:30 a.m. EST on:

Nykode Therapeutics - Quarterly report Q3 2023

Retrieved on: 
Wednesday, November 15, 2023

OSLO, Norway, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced its unaudited financial results for the third quarter of 2023.

Key Points: 
  • OSLO, Norway, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced its unaudited financial results for the third quarter of 2023.
  • The financial report can be accessed in the Investors section of the Company’s website: https://nykode.com/investors/financial-reports-and-presentations
    The Company will host a webcast presentation at 4 p.m. CET / 10 a.m.
  • ET.
  • A live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website and on the following link: https://event.webcasts.com/starthere.jsp?ei=1640257&tp_key=2a6664ef92

Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors

Retrieved on: 
Wednesday, November 15, 2023

As part of the proposed changes, three current Supervisory Board members will not join the future Board of Directors, Ms. Johanna Pattenier, Ms. Sharon Tetlow and Mr. Frederic Grimaud, current Chairman of the Supervisory Board.

Key Points: 
  • As part of the proposed changes, three current Supervisory Board members will not join the future Board of Directors, Ms. Johanna Pattenier, Ms. Sharon Tetlow and Mr. Frederic Grimaud, current Chairman of the Supervisory Board.
  • I wish Valneva every success in the future,” said Frederic Grimaud, Valneva’s Chairman of the Board and Groupe Grimaud’s President and Chief Executive Officer.
  • The future Board of Directors is expected to elect a new chairperson during its constitutional post EGM meeting.
  • The Company also intends to propose additional, complementary Board of Directors members to its shareholders at its Annual General Meeting in June 2024.

PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023

Retrieved on: 
Tuesday, November 14, 2023

The enrollment is targeted to start by the end of 2023 and the first study results are expected in mid-2024.

Key Points: 
  • The enrollment is targeted to start by the end of 2023 and the first study results are expected in mid-2024.
  • Key financial figures for the first nine months of 2023 compared with the same period of the previous year are summarized below.
  • In the context of the Erytech-Pherecydes merger, PHAXIAM’s consolidated financial statements in IFRS standards include ex-Pherecydes financial results as from the date of the merger, i.e.
  • Consequently, PHAXIAM’s P&L information for the first 9 months of 2023 include 9 months of ex-Erytech activities and ex-Pherecydes activities since June 23, 2023.

Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference

Retrieved on: 
Tuesday, November 14, 2023

PARIS, France, November 14, 2023, 2:00 p.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced that management will be holding meetings with investors and presenting a corporate overview at the upcoming Piper Sandler 35th Annual Healthcare Conference taking place in New York on November 28-30, 2023.

Key Points: 
  • PARIS, France, November 14, 2023, 2:00 p.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced that management will be holding meetings with investors and presenting a corporate overview at the upcoming Piper Sandler 35th Annual Healthcare Conference taking place in New York on November 28-30, 2023.
  • To enter the live webcast, please click here .
  • The link to the live webcast of the presentation may also be accessed under “News & Events” on the Investor Relations section of the Abivax website at www.abivax.com .
  • A replay of the webcast will be available on the Company’s website for approximately three months.

Pixium Vision announces the 48-Month Trial Results in Severe Atrophic AMD

Retrieved on: 
Tuesday, November 14, 2023

Using the prosthetic central vision provided by PRIMA, patients reliably recognized letters and sequences of letters with a clinically meaningful improvement in visual acuity of up to eight lines.

Key Points: 
  • Using the prosthetic central vision provided by PRIMA, patients reliably recognized letters and sequences of letters with a clinically meaningful improvement in visual acuity of up to eight lines.
  • As a reminder, the Company is currently subject to receivership proceedings and is actively looking for buyers to acquire the Company’s business.
  • The deadline for submission of offers has been set to November 20, 2023, at 12:00 p.m. (noon) CET.
  • Pixium will continue to regularly inform the market on the progress of the procedure and, more generally, of Pixium Vision’s financial situation.

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

Retrieved on: 
Monday, November 13, 2023

PARIS and CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and reported financial results for the third quarter of 2023.

Key Points: 
  • “Our robust NBTXR3 clinical program continues to demonstrate potentially transformative efficacy and well-tolerated safety across indications and patient types, including elderly and vulnerable populations.
  • Nanobiotix will host a conference call and live audio webcast on Tuesday, November 14, 2023, at 8:00 am ET / 2:00 pm CET, prior to the open of the U.S. market.
  • During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company’s operational progress, provide an update on business activities for the third quarter of 2023, and review the latest data presented at the 2023 Annual Congress of the European Society for Medical Oncology (ESMO), before taking questions from participants.
  • A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website.

Sequana Medical announces results of Extraordinary General Meeting of Shareholders

Retrieved on: 
Friday, November 10, 2023

Ghent, Belgium – 10 November 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all proposed resolutions submitted to the Extraordinary General Meeting of Shareholders were approved at the meeting held today at 09:00 am CET.

Key Points: 
  • Ghent, Belgium – 10 November 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all proposed resolutions submitted to the Extraordinary General Meeting of Shareholders were approved at the meeting held today at 09:00 am CET.
  • The minutes of the shareholders' meeting can be accessed on the Company's website .
  • Ids van der Weij is Managing Partner of Partners in Equity V ("PiE V"), a private investment firm focusing on, among others, life sciences.
  • Pierre Chauvineau, Chairman of Sequana Medical's Board of Directors, commented: “We are delighted to welcome Ids to our Board of Directors.

MaaT Pharma to Host Virtual KOL Event on MaaT013 and MaaT033 Following ASH 2023 Presentations

Retrieved on: 
Tuesday, December 12, 2023

---

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, announced that it will host a virtual KOL (Key Opinion Leader) event on data presented during the 2023 ASH annual meeting including efficacy and safety results for its lead drug candidate, MaaT013, currently in development for acute Graft-versus-Host Disease (aGvHD) and details on MaaT033, developed as an adjuvant therapy to improve patients’ survival following allogeneic hematopoietic stem cell transplantation (allo-HSCT), on Monday, December 18, 2023, at 6:00 pm CET (12:00 pm EST).
  • The event will feature presentations from the Company’s CEO and co-founder, Hervé Affagard as well as the following KOLs:
    Mohamad Mohty, M.D., Ph.D., Professor of Hematology at Sorbonne University, and head of the Clinical Hematology and Cellular Therapy Department at Saint-Antoine Hospital, Paris, France will comment on the positive data on MaaT013 presented for the Early Access Program; and
    Florent Malard, M.D., Ph.D., Professor of Hematology at the Saint-Antoine Hospital and Sorbonne University, Principal investigator of Phase 2b trial evaluating MaaT033 in patients receiving allo-HSCT, will provide detailed information on the ongoing trial.
  • Registration & link to access the event: https://app.livestorm.co/newcap-1/maat-pharma-presentation?type=detailed
    A replay will be made available on the Company’s website for at least 90 days.

MaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase 2b Trial with MaaT033 at ASH 2023

Retrieved on: 
Monday, December 11, 2023

“It reinforces our approach based on restoring patients’ immune systems through gut microbiome ecosystem therapies.

Key Points: 
  • “It reinforces our approach based on restoring patients’ immune systems through gut microbiome ecosystem therapies.
  • OS was 56% at 6 months and 47% at 12 months with a median follow up of 355 days.
  • A Phase 3 trial is currently ongoing in Europe to confirm these results in ruxolitinib-refractory patients ( NCT04769895 ) with ORR expected in mid-2024.
  • MaaT Pharma also presented its ongoing Phase 2b trial design for MaaT033, its second candidate, at the 2023 ASH Annual Meeting.